ArticleBMC pulmonary medicine2026
Nintedanib alleviates pulmonary inflammation and fibrosis in mice with silicosis.
Article in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveThis study aimed to evaluate nintedanib's therapeutic effects on mice silicosis by examining pulmonary function, lung inflammation, and fibrosis.
methodsMice were categorized into preventive and therapeutic groups, each with control, low-dose, and high-dose treatment subgroups. Cell counts in bronchoalveolar lavage fluid and cytokines in the lung tissue were detected using quantitative polymerase chain reaction. The right ventricular hypertrophy index (RVHI) was assessed, and lung collagen deposition and inflammation were analyzed using various histological and molecular techniques. Forced lung function tests were conducted to evaluate lung compliance, total lung capacity (TLC), and the mouse airway resistance.
resultsIn the preventive group, neutrophil counts and levels of pro-inflammatory cytokines in lung tissue were significantly lower in the treatment group than in the control group, with no significant differences in the RVHI. Collagen deposition and pathological scores for inflammation and fibrosis were reduced in the treatment group. In lung function tests, TLC was higher and resistance lower in the high-dose group. In the therapeutic group, cytokine levels and the RVHI were significantly lower in the treatment group, while collagen type I mRNA expression was statistically significant. Lung function tests revealed improved TLC and resistance in the treatment group.
conclusionNintedanib reduces lung inflammation, fibrosis, and right ventricular hypertrophy in mice with silicosis, demonstrating potential therapeutic effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.